Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review
Simple Summary 1. Treatment outcomes for urothelial carcinoma have significantly improved recently due to advancements in antibody-based therapies, particularly immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs). 2. ICIs enhance the patient’s immune response against cancer cells, whereas ADCs selec...